
Olio Labs
Combinatorial therapeutics for the world's toughest diseases.
Date | Investors | Amount | Round |
---|---|---|---|
investor investor investor investor investor | €0.0 | round | |
* | $4.5m | Early VC | |
Total Funding | 000k |
Related Content
Olio Labs leverages artificial intelligence to develop therapeutics that address the complex interactions of thousands of proteins within the human body, rather than focusing on just one or two. This approach aims to create more effective treatments with fewer side effects, positioning the company in the biopharmaceutical sector. Olio Labs primarily serves the healthcare market, targeting conditions that require advanced therapeutic solutions. The business model revolves around research and development of AI-driven drug combinations, potentially generating revenue through partnerships, licensing, and direct sales of their therapeutic solutions. The company is led by experienced professionals with backgrounds in systems neuroscience, biology, and technology development, bringing a wealth of expertise to their innovative approach.
Keywords: AI, therapeutics, protein interactions, healthcare, biopharmaceutical, drug development, neuroscience, systems biology, R&D, treatments.